期刊
MEDICINAL RESEARCH REVIEWS
卷 41, 期 1, 页码 275-313出版社
WILEY
DOI: 10.1002/med.21732
关键词
arrhythmias; atherosclerosis; cardiomyopathy; cardiovascular disease; heart failure; hypertension; mitochondria; mitochondrial DNA; mitochondrial dysfunction
资金
- Sanofi
- Mylan
- NovoNordisk
- Boehringer Ingelheim
- WinMedica
Mitochondria play a crucial role in providing energy for cells and have various functions beyond energy production. Dysfunction of mitochondria can lead to cardiomyopathies and other cardiovascular diseases, often caused by mutations in mitochondrial or nuclear DNA, as well as aging, disease, and environmental stresses. Developing targeted therapeutic strategies for mitochondria remains a challenge due to variable responses based on the underlying causes of dysfunction.
Mitochondria provide energy to the cell during aerobic respiration by supplying similar to 95% of the adenosine triphosphate (ATP) molecules via oxidative phosphorylation. These organelles have various other functions, all carried out by numerous proteins, with the majority of them being encoded by nuclear DNA (nDNA). Mitochondria occupy similar to 1/3 of the volume of myocardial cells in adults, and function at levels of high-efficiency to promptly meet the energy requirements of the myocardial contractile units. Mitochondria have their own DNA (mtDNA), which contains 37 genes and is maternally inherited. Over the last several years, a variety of functions of these organelles have been discovered and this has led to a growing interest in their involvement in various diseases, including cardiovascular (CV) diseases. Mitochondrial dysfunction relates to the status where mitochondria cannot meet the demands of a cell for ATP and there is an enhanced formation of reactive-oxygen species. This dysfunction may occur as a result of mtDNA and/or nDNA mutations, but also as a response to aging and various disease and environmental stresses, leading to the development of cardiomyopathies and other CV diseases. Designing mitochondria-targeted therapeutic strategies aiming to maintain or restore mitochondrial function has been a great challenge as a result of variable responses according to the etiology of the disorder. There have been several preclinical data on such therapies, but clinical studies are scarce. A major challenge relates to the techniques needed to eclectically deliver the therapeutic agents to cardiac tissues and to damaged mitochondria for successful clinical outcomes. All these issues and progress made over the last several years are herein reviewed.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据